B55 Leishmaniasis

Name of the Condition

• Leishmaniasis

Summary

Leishmaniasis is a parasitic disease caused by protozoa of the genus Leishmania. It is transmitted through the bite of infected sandflies and can manifest in several clinical forms, including cutaneous, mucocutaneous, and visceral (kala-azar) leishmaniasis. The condition ranges from self-healing skin lesions to severe, life-threatening systemic disease, depending on the parasite species and host immune response.

Causes

Leishmaniasis is caused by Leishmania parasites, which are transmitted to humans through the bite of infected female sandflies of the genus Phlebotomus (Old World) or Lutzomyia (New World). The parasites enter the skin during feeding, multiply within macrophages, and can disseminate to other tissues, leading to the varied clinical presentations of the disease.

Risk Factors

• Exposure to sandfly habitats, such as rural or tropical regions where the insects breed.
• Immunocompromised states, including HIV/AIDS, organ transplantation, or chemotherapy.
• Malnutrition or other conditions that weaken the immune system.
• Travel to or residence in endemic areas, particularly in parts of Asia, Africa, Latin America, and the Mediterranean.

Symptoms

• Cutaneous leishmaniasis: Painless or mildly painful skin ulcers, often with a raised border, that may heal slowly.
• Mucocutaneous leishmaniasis: Destruction of mucous membranes, such as the nose or mouth, leading to disfigurement.
• Visceral leishmaniasis: Fever, weight loss, enlarged spleen and liver, and anemia, which can be fatal if untreated.

Diagnosis

Diagnosis is confirmed by identifying Leishmania parasites in tissue samples, such as skin scrapings, biopsy specimens, or bone marrow aspirates. Microscopic examination, culture, or molecular tests (e.g., PCR) may be used. Serological tests or antigen detection can support diagnosis, especially for visceral forms.

Treatment Options

Treatment depends on the form and severity of the disease. Cutaneous leishmaniasis may resolve spontaneously or require topical or systemic antiparasitic medications (e.g., pentavalent antimonials, miltefosine). Visceral leishmaniasis typically requires intravenous or oral antiparasitic therapy, often in combination with supportive care for anemia or organ dysfunction.

Prognosis and Follow-Up

Prognosis varies by disease form: cutaneous leishmaniasis generally has a good outcome with treatment, while visceral leishmaniasis can be fatal if untreated. Follow-up includes monitoring for treatment response, resolution of symptoms, and detection of relapse, particularly in immunocompromised patients.

Complications

• Disfigurement from mucocutaneous lesions.
• Organ damage or failure in severe visceral cases.
• Secondary bacterial infections in skin ulcers.
• Post-kala-azar dermal leishmaniasis, a late skin manifestation after visceral disease.

Lifestyle & Prevention

• Avoid sandfly bites by using insect repellent, wearing protective clothing, and sleeping under insecticide-treated nets.
• Control sandfly populations in endemic areas through environmental management.
• Screen and treat infected individuals to reduce transmission in high-risk regions.

When to Seek Professional Help

Seek medical attention if you develop persistent skin ulcers, unexplained fever, weight loss, or signs of organ enlargement after travel to or residence in an endemic area. Early diagnosis and treatment improve outcomes, especially for visceral leishmaniasis.

Tips for Medical Coders

Code B55 is used for leishmaniasis, including all clinical forms (cutaneous, mucocutaneous, visceral). Document the specific type and any associated complications to ensure accurate coding. Note that leishmaniasis is reportable in many regions, so confirm local documentation requirements.